oral semaglutide launch Novo Nordisk to Ozempic for type 2 diabetes in US Oral GLP-1 Wegovy chases approval

In addition, semaglutide causes central c-Fos activation in eleven brain regions, including secondary regions devoid of direct GLP-1R interaction and portions of the hindbrain that are directly targeted by the drug

One meta-analysis compared the highest dose of tirzepatide (15 mg) to the highest dose of semaglutide (2 mg) and found that tirzepatide resulted in a greater weight loss at a 17.8% reduction in body weight versus 12.4% for semaglutide

B12 is essential for the proper functioning of the nervous system and the production of red blood cells, making these injections an important tool in overall wellness

Retatrutide is an investigational triple GLP-1/GIP/glucagon receptor agonist not approved by the MHRA or EMA

Normal muscle maintenance following physical activity*1,3,10

This graduated approach minimizes side effects while progressively increasing therapeutic benefit